drugset / Trial / NCT02398136

To Test the Potential Efficacy of Repeated Intranasal Administration of Ketamine as a Treatment for PTSD

NCT02398136 ↗

Phase 2/3 Withdrawn Adriana Feder
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to see whether ketamine, when given repeatedly via the nose (intranasally), can produce a quick and persistent improvement in PTSD symptoms. At higher doses, ketamine has been used for many years as an anesthetic for medical procedures, and at lower doses may be an effective treatment in patients with major depression and PTSD.

Timeline

Start
2014-12
Primary completion
2014-12
Completion
2014-12

Outcome

Outcome not reported

Stopped: “FDA and IRB recommended different mode of medication administration”

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 75 mg Intranasal
Comparator Midazolam Small molecule 3.75 mg Intranasal